Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ischemia-tolerant allogeneic mesenchymal bone marrow cells
- Development stage
- Phase 2
- Lead developer
- Mayo Clinic
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous, Intraarticular
01
Overview
**Ischemia-tolerant allogeneic mesenchymal bone marrow cells** are a cell therapy product consisting of mesenchymal stem cells (MSCs) derived from allogeneic human bone marrow, engineered or selected for enhanced tolerance to ischemic conditions. These cells exert immunomodulatory and anti-inflammatory effects by secreting paracrine factors that restore homeostasis in the neuronal-glial microenvironment, reduce neuroinflammation, and potentially mitigate tissue damage in ischemic or degenerative settings. Primarily investigated for neurodegenerative and inflammatory diseases, they have shown preliminary safety in intravenous or intra-articular administration across phase 1/2 trials, with developers including academic centers like Mayo Clinic.
- Other names
- allogeneic bone marrow-derived mesenchymal stem cellsallogeneic BM-MSCsbone marrow-derived MSCs
Beyond the preview
Go deeper on ischemia-tolerant allogeneic mesenchymal bone marrow cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ischemia-tolerant allogeneic mesenchymal bone marrow cells.